Northern Trust’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-62,186
| Closed | -$930K | – | 4710 |
|
|
2022
Q4 | $930K | Buy |
62,186
+11,745
| +23% | +$163K | ﹤0.01% | 3283 |
|
|
2022
Q3 | $415K | Sell |
50,441
-1,705
| -3% | -$13.1K | ﹤0.01% | 3577 |
|
|
2022
Q2 | $342K | Sell |
52,146
-1,401
| -3% | -$6.79K | ﹤0.01% | 3674 |
|
|
2022
Q1 | $300K | Sell |
53,547
-3,397
| -6% | -$14K | ﹤0.01% | 3949 |
|
|
2021
Q4 | $267K | Sell |
56,944
-2,237
| -4% | -$13.9K | ﹤0.01% | 4078 |
|
|
2021
Q3 | $367K | Buy |
59,181
+3,188
| +6% | +$19.1K | ﹤0.01% | 3887 |
|
|
2021
Q2 | $369K | Sell |
55,993
-172,793
| -76% | -$1.19M | ﹤0.01% | 3846 |
|
|
2021
Q1 | $1.68M | Sell |
228,786
-14,053
| -6% | -$121K | ﹤0.01% | 3341 |
|
|
2020
Q4 | $1.4M | Buy |
242,839
+14,470
| +6% | +$82.8K | ﹤0.01% | 3366 |
|
|
2020
Q3 | $1.36M | Buy |
228,369
+67,152
| +42% | +$332K | ﹤0.01% | 3244 |
|
|
2020
Q2 | $830K | Buy |
161,217
+136,348
| +548% | +$861K | ﹤0.01% | 3418 |
|
|
2020
Q1 | $90K | Sell |
24,869
-3
| -0% | -$15 | ﹤0.01% | 3841 |
|
|
2019
Q4 | $155K | Hold |
24,872
| – | – | ﹤0.01% | 3852 |
|
|
2019
Q3 | $210K | Sell |
24,872
-86,746
| -78% | -$646K | ﹤0.01% | 3757 |
|
|
2019
Q2 | $751K | Sell |
111,618
-6,266
| -5% | -$53.7K | ﹤0.01% | 3444 |
|
|
2019
Q1 | $967K | Buy |
117,884
+324
| +0.3% | +$3.35K | ﹤0.01% | 3373 |
|
|
2018
Q4 | $1.88M | Buy |
117,560
+3,416
| +3% | +$75.2K | ﹤0.01% | 3093 |
|
|
2018
Q3 | $3.78M | Buy |
114,144
+4,336
| +4% | +$111K | ﹤0.01% | 2859 |
|
|
2018
Q2 | $2.48M | Buy |
109,808
+87,671
| +396% | +$2.08M | ﹤0.01% | 3091 |
|
|
2018
Q1 | $642K | Buy |
22,137
+1,534
| +7% | +$44.9K | ﹤0.01% | 3506 |
|
|
2017
Q4 | $575K | Hold |
20,603
| – | – | ﹤0.01% | 3529 |
|
|
2017
Q3 | $752K | Buy |
20,603
+8,975
| +77% | +$278K | ﹤0.01% | 3502 |
|
|
2017
Q2 | $259K | Hold |
11,628
| – | – | ﹤0.01% | 3721 |
|
|
2017
Q1 | $69K | Buy |
11,628
+1,044
| +10% | +$7.54K | ﹤0.01% | 4019 |
|
|
2016
Q4 | $57K | Buy |
10,584
+367
| +4% | +$2.45K | ﹤0.01% | 3993 |
|
|
2016
Q3 | $91K | Hold |
10,217
| – | – | ﹤0.01% | 3914 |
|
|
2016
Q2 | $98K | Buy |
10,217
+2,812
| +38% | +$27.1K | ﹤0.01% | 3893 |
|
|
2016
Q1 | $68K | Hold |
7,405
| – | – | ﹤0.01% | 3975 |
|
|
2015
Q4 | $94K | Hold |
7,405
| – | – | ﹤0.01% | 3952 |
|
|
2015
Q3 | $89K | Buy |
7,405
+132
| +2% | +$1.91K | ﹤0.01% | 3958 |
|
|
2015
Q2 | $126K | Sell |
7,273
-2,121
| -23% | -$38.2K | ﹤0.01% | 3898 |
|
|
2015
Q1 | $136K | Sell |
9,394
-190
| -2% | -$2.08K | ﹤0.01% | 3973 |
|
|
2014
Q4 | $80K | Buy |
9,584
+52
| +0.5% | +$475 | ﹤0.01% | 4019 |
|
|
2014
Q3 | $106K | Sell |
9,532
-41,748
| -81% | -$531K | ﹤0.01% | 4007 |
|
|
2014
Q2 | $938K | Sell |
51,280
-11,604
| -18% | -$151K | ﹤0.01% | 3417 |
|
|
2014
Q1 | $940K | Sell |
62,884
-8,792
| -12% | -$158K | ﹤0.01% | 3412 |
|
|
2013
Q4 | $1.31M | Buy |
71,676
+2,450
| +4% | +$49.1K | ﹤0.01% | 3315 |
|
|
2013
Q3 | $1.43M | Buy |
69,226
+2,372
| +4% | +$54.3K | ﹤0.01% | 3235 |
|
|
2013
Q2 | $1.67M | Buy |
+66,854
| New | +$2.86M | ﹤0.01% | 3083 |
|
Northern Trust's AVEO Position: Q1 2023 in Review
Northern Trust sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 62,186 shares — an estimated $930K sold.
Northern Trust first reported a position in AVEO in Q2 2013 and held it in 39 quarters. The position peaked at $3.78M in Q3 2018. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- Northern Trust reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Northern Trust sold 62,186 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $930K.
- Northern Trust first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 39 quarters.
- Northern Trust's AVEO Pharmaceuticals, Inc. position peaked at $3.78M in Q3 2018.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on Northern Trust's 13F filing for Q1 2023, filed 15 May 2023.